COVID-19 Archives - Page 9 of 16

Markets

Analysts offer mixed reviews of T2 Biosystems preliminary Q4 results

Analysts for BTIG, Canaccord Genuity and Alliance Global Partners had mixed reviews of preliminary fourth quarter results for T2 Biosystems (NASDAQ:TTOO),a leader in the rapid detection of sepsis-causing pathogens. Mark...

January 27, 2021

Developments

Soricimed approach to COVID-19 being validated by other researchers

Researchers at Rush University Medical Center in Chicago are developing a new peptide treatment to prevent COVID-19 symptoms that supports the approach being taken by closely-held Soricimed Biopharma. The peptide...

January 25, 2021

Developments

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

aTyr Pharma (NASDAQ:LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do...

January 5, 2021

Developments

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

The FDA accepted an IND application from Hepion Pharmaceuticals (NASDAQ:HEPA) for the use of CRV431, a novel cyclophilin inhibitor, for the treatment of COVID-19. Hepion is developing CRV431 as part of its artificial...

December 22, 2020

Developments

Soricimed to investigate SOR-C13 to treat COVID-19

Closely-held Soricimed Biopharma, benefiting from funding support from the National Research Council of Canada Industrial Research Assistance Program, will investigate the potential therapeutic role its cancer drug...

December 17, 2020

Markets

BTIG starts Aerpio Pharma at buy: PT $4

BTIG launched coverage of Aerpio Pharmaceuticals (NASDAQ:ARPO) with a “buy” rating and $4 price target. The stock closed at $2 on Dec. 8. “Aerpio is marching forward with several clinical programs of its first-in-class...

December 9, 2020

Developments

Capricor initiates dosing in Phase 2 COVID-19 trial

Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...

November 24, 2020

Markets

Analysts start Biodesix at buy and OP

Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

November 23, 2020

Developments

Humanigen reports positive interim data from Phase 3 COVID-19 trial

Humanigen (NASDAQ:HGEN) reported positive interim results from its Phase 3 trial evaluating lenzilumab in hospitalized COVID-19 patients. Lenzilumab is an antibody that targets granulocyte-macrophage colony-stimulating...

November 6, 2020

Markets

SVB Leerink ups Inflarx to OP; PT to $10 from $7

SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...

November 6, 2020

Tag - COVID-19

Analysts offer mixed reviews of T2 Biosystems preliminary Q4 results

Soricimed approach to COVID-19 being validated by other researchers

aTyr Pharma posts positive topline results from Phase 2 COVID-19 study

FDA accepts Hepion Pharma IND for CRV431 to treat COVID-19

Soricimed to investigate SOR-C13 to treat COVID-19

BTIG starts Aerpio Pharma at buy: PT $4

Capricor initiates dosing in Phase 2 COVID-19 trial

Analysts start Biodesix at buy and OP

Humanigen reports positive interim data from Phase 3 COVID-19 trial

SVB Leerink ups Inflarx to OP; PT to $10 from $7

Subscribe